# Sources and acknowledgments

> Mar 12th 2020

Many people contributed their time and energy to this Technology Quarterly. In addition to those quoted in the article, the author would like to thank: Dan Budwick, Thomas Gardella, Christiane Hertz-Fowler, Harald Jueppner, Sabita Sankar, Aviv Regev, Mike Turner, and Raquel Yotti.

Further reading and sources are listed below:

The human genome project, genomics & disease

Lewin R. Proposal to sequence the human genome stirs debate. Science. 1986;232(4758):1598-1600.

Sulston J, Ferry G. The Common Thread: A Story of Science, Politics, Ethics, and the Human Genome. Washington, D.C: Joseph Henry Press; 2002.

Mukherjee S. The Gene: An Intimate History. First Scribner hardcover edition. New York: Scribner; 2016.

Hunter DJ, Drazen JM. Has the Genome Granted Our Wish Yet? N Engl J Med. 2019;380(25):2391-2393.

Collins FS. Medical and Societal Consequences of the Human Genome Project. N Engl J Med. 1999;341(1):28-37.

Connor S. Ten years ago today, it was revealed that the human genome had been decoded. A medical revolution beckoned. So what happened next? Independent. June 26, 2010.

Pearson H. Human genetics: One gene, twenty years. Nature. 2009;460(7252):164-169.

Joyner MJ, Paneth N. Promises, promises, and precision medicine. Journal of Clinical Investigation. 2019;129(3):946-948.

Davies S. Annual Report of the Chief Medical Officer, 2016. Generation Genome. Department of Health and Social Care; 2016.

Buchanan J, Wordsworth S. Evaluating the Outcomes Associated with Genomic Sequencing: A Roadmap for Future Research. PharmacoEconomics Open. 2019;3(2):129-132.

Joseph A. A clinical trial for Huntington’s opens the door to hope for some patients. Only so many can get in. Statnews.[https://www.statnews.com/2019/12/04/a-clinical-trial-for-huntingtons-opens-the-door-to-hope-for-some-patients-but-only-so-many-can-get-in/](https://www.economist.com/https://www.statnews.com/2019/12/04/a-clinical-trial-for-huntingtons-opens-the-door-to-hope-for-some-patients-but-only-so-many-can-get-in/). Published December 4, 2019.

Ioannidis JPA, Khoury MJ. Evidence-based medicine and big genomic data. Human Molecular Genetics. 2018;27(R1):R2-R7.

Lawton M, Ben-Shlomo Y, May MT, et al. Developing and validating Parkinson’s disease subtypes and their motor and cognitive progression. J Neurol Neurosurg Psychiatry. 2018;89(12):1279-1287.

From 6 million to 1 – Jessica’s story.[https://www.genomicsengland.co.uk/understanding-genomics/jessicas-story/](https://www.economist.com/https://www.genomicsengland.co.uk/understanding-genomics/jessicas-story/).

MEET THE RARE FAMILY WHO ACCOUNT FOR 10% OF ALL CASES OF JANSEN’S.[https://www.thejansensfoundation.org/blog-1/2019/2/19/meet-the-rare-family-who-account-for-10-of-all-cases-of-jansens](https://www.economist.com/https://www.thejansensfoundation.org/blog-1/2019/2/19/meet-the-rare-family-who-account-for-10-of-all-cases-of-jansens). Published February 19, 2019.

Riboflavin Treatment for Childhood onset Motor Neuron Disease.[https://www.ucl.ac.uk/ion/news/2013/dec/riboflavin-treatment-childhood-onset-motor-neuron-disease](https://www.economist.com/https://www.ucl.ac.uk/ion/news/2013/dec/riboflavin-treatment-childhood-onset-motor-neuron-disease). Published December 5, 2013.

Kolata G. Scientists Designed a Drug for Just One Patient. Her Name Is Mila. New York Times. October 9, 2019.

Genetic testing improves blood thinner dosing. National Institutes of Health.[https://www.nih.gov/news-events/nih-research-matters/genetic-testing-improves-blood-thinner-dosing](https://www.economist.com/https://www.nih.gov/news-events/nih-research-matters/genetic-testing-improves-blood-thinner-dosing). Published October 3, 2017.

Loder N. In 2020 a father will create a new drug to try to save his daughter’s life. The World In 2020. [https://worldin.economist.com/article/17520/edition2020creating-personalised-drugs?category=extra&navigation=true](https://www.economist.com/https://worldin.economist.com/article/17520/edition2020creating-personalised-drugs?category=extra&navigation=true).

Polygenic risk scores 

Regalado A. 23andMe thinks polygenic risk scores are ready for the masses, but experts aren’t so sure.[https://www.technologyreview.com/s/613095/23andme-thinks-polygenic-risk-scores-are-ready-for-the-masses-but-experts-arent-so-sure/](https://www.economist.com/https://www.technologyreview.com/s/613095/23andme-thinks-polygenic-risk-scores-are-ready-for-the-masses-but-experts-arent-so-sure/). Published March 8, 2019.

Stower H. Bringing polygenic risk scores to the clinic. Nat Med. 2018;24(9):1303-1303.

Ampong DN. Depression and Pharmacogenetics. Archives of Psychiatric Nursing. 2018;32(1):71-74.

Khera AV, Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50(9):1219-1224.

Kullo IJ, Jouni H, Austin EE, et al. Incorporating a Genetic Risk Score Into Coronary Heart Disease Risk Estimates: Effect on Low-Density Lipoprotein Cholesterol Levels (the MI-GENES Clinical Trial). Circulation. 2016;133(12):1181-1188.

Mavaddat N, Michailidou K, Dennis J, et al. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. The American Journal of Human Genetics. 2019;104(1):21-34.

Hollands GJ, French DP, Griffin SJ, et al. The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis. BMJ. 2016;352:i1102.

Drug development

Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012;11(3):191-200.

Dugger SA, Platt A, Goldstein DB. Drug development in the era of precision medicine. Nat Rev Drug Discov. 2018;17(3):183-196.

Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20(2):273-286.

Gabriel K. How to Fight “Eroom’s Law” Human organs on a chip might be able to cure what ails pharma R&D. Scientific American. July 2019.[https://blogs.scientificamerican.com/observations/how-to-fight-erooms-law/](https://www.economist.com/https://blogs.scientificamerican.com/observations/how-to-fight-erooms-law/).

Data and digital health

OECD. Health in the 21st Century: Putting Data to Work for Stronger Health Systems. OECD; 2019.

Liu X, Faes L, Kale AU, et al. A comparison of deep learning performance against health-care professionals in detecting diseases from medical imaging: a systematic review and meta-analysis. The Lancet Digital Health. 2019;1(6):e271-e297.

Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56.

Kelly CJ, Karthikesalingam A, Suleyman M, Corrado G, King D. Key challenges for delivering clinical impact with artificial intelligence. BMC Med. 2019;17(1):195.

Singer N. These Apps Say You May Have a Health Disorder. What if They’re Wrong? New York Times. October 27, 2019.

Larsen ME, Huckvale K, Nicholas J, et al. Using science to sell apps: Evaluation of mental health app store quality claims. npj Digit Med. 2019;2(1):18. 

## URL

https://www.economist.com/technology-quarterly/2020/03/12/sources-and-acknowledgments
